Autoantibodies to pyruvate dehydrogenase complex in patients with systemic sclerosis. Possible role of anti-E1 alpha antibody as a serologic indicator for development of primary biliary cirrhosis

Arthritis Rheum. 1995 Jul;38(7):985-9. doi: 10.1002/art.1780380715.


Objective: To determine the prevalence and clinical significance of anti-pyruvate dehydrogenase complex (anti-PDC) antibodies in systemic sclerosis (SSc).

Methods: Serum samples from patients with limited cutaneous SSc (n = 81) or diffuse cutaneous SSc (n = 63) were examined for anti-PDC antibodies by enzyme-linked immunosorbent assay (ELISA) and immunoblotting.

Results: IgG- and/or IgM-isotype anti-PDC antibodies were demonstrated by ELISA in 26 of 144 patients with SSc (18%). By immunoblotting, 19 patients had IgG anti-PDC antibodies. Among these patients with IgG anti-PDC antibodies, antibody to the E1 alpha subunit was significantly associated with the presence of laboratory abnormalities typical of primary biliary cirrhosis (PBC).

Conclusion: Antibody to the E1 alpha subunit of PDC may be a serologic indicator for the development of PBC in patients with SSc.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Autoantibodies / analysis
  • Autoantibodies / blood*
  • Biomarkers / analysis
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunoblotting
  • Liver Cirrhosis, Biliary / epidemiology*
  • Liver Cirrhosis, Biliary / etiology
  • Liver Cirrhosis, Biliary / immunology
  • Middle Aged
  • Predictive Value of Tests
  • Pyruvate Dehydrogenase Complex / immunology*
  • Risk Factors
  • Scleroderma, Systemic / complications
  • Scleroderma, Systemic / enzymology*
  • Scleroderma, Systemic / immunology*


  • Autoantibodies
  • Biomarkers
  • Pyruvate Dehydrogenase Complex